Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 04, 2021 08:00 ET | Source: Ovid Therapeutics Inc.

Ovid Therapeutics Appoints Jeff Rona as Chief Business and Financial Officer

NEW YORK, June 04, 2021 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare...
May 26, 2021 08:00 ET | Source: Ovid Therapeutics Inc.

Ovid Therapeutics Appoints Dr. Joy A. Cavagnaro and Dr. Bruce A. Sullenger to its Scientific Advisory Board

New appointments strengthen neuroscience-focused Scientific Advisory Board NEW YORK, May 26, 2021 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to...
May 13, 2021 16:05 ET | Source: Ovid Therapeutics Inc.

Ovid Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update

Closed royalty, license and termination agreement with Takeda for soticlestat; Ovid Therapeutics received an upfront payment of $196.0 million and is eligible to receive up to $660.0 million in...
May 12, 2021 08:00 ET | Source: Ovid Therapeutics Inc.

Ovid Therapeutics to Participate in the 2021 RBC Capital Markets Global Healthcare Conference

NEW YORK, May 12, 2021 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare...
April 20, 2021 08:00 ET | Source: Ovid Therapeutics Inc.

Ovid Therapeutics Announces Appointment of Professor Robert S. Langer, Sc.D., as Chair of its Scientific Advisory Board

NEW YORK, April 20, 2021 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare...
April 19, 2021 08:00 ET | Source: Ovid Therapeutics Inc.

OVID Provides Update on OV101 Program and the Prioritization of its Resources

Completed Soticlestat Agreement with Takeda Provides Significant Resources to Advance and Enrich OVID’s Pipeline, Including OV882 for Angelman Syndrome Company Reiterates Anticipated Quarterly...
March 30, 2021 08:00 ET | Source: Ovid Therapeutics Inc.

Ovid Therapeutics Announces Closing of Agreement with Takeda for Global Development and Commercialization of Soticlestat

NEW YORK, March 30, 2021 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID) (“Ovid”), a biopharmaceutical company committed to developing medicines that transform the lives of people with...
March 15, 2021 08:00 ET | Source: Ovid Therapeutics Inc.

Ovid Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results, Provides Corporate Update for 2021

Announced signing of transaction transferring Ovid’s 50% of global rights to develop and commercialize soticlestat (TAK-935/OV935) to Takeda, under which Ovid is eligible to receive up to $856 million...
December 16, 2020 07:00 ET | Source: Ovid Therapeutics Inc.

Ovid Therapeutics Announces Addition to the Nasdaq Biotechnology Index

NEW YORK, Dec. 16, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare...
December 01, 2020 16:52 ET | Source: Ovid Therapeutics Inc.

Ovid Therapeutics Announces Phase 3 NEPTUNE Clinical Trial of OV101 for the Treatment of Angelman Syndrome Did Not Meet Primary Endpoint

OV101 program in Angelman syndrome to pause pending full analysis of NEPTUNE trial and discussions with FDAPivotal studies of OV935 (soticlestat) in Dravet syndrome and Lennox-Gastaut syndrome...